tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), BellRing Brands (BRBR) and Optinose (OPTN)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGNResearch Report), BellRing Brands (BRBRResearch Report) and Optinose (OPTNResearch Report) with bullish sentiments.

Regeneron (REGN)

BMO Capital analyst Evan Seigerman reiterated a Buy rating on Regeneron today and set a price target of $780.00. The company’s shares closed last Friday at $622.96.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 8.5% and a 42.0% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Mirati Therapeutics, and Gilead Sciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $706.80 average price target, implying a 15.9% upside from current levels. In a report issued on January 31, Truist Financial also maintained a Buy rating on the stock with a $754.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BellRing Brands (BRBR)

In a report released today, Kenneth Zaslow from BMO Capital maintained a Buy rating on BellRing Brands, with a price target of $33.00. The company’s shares closed last Friday at $23.01.

According to TipRanks.com, Zaslow is a 5-star analyst with an average return of 11.7% and a 69.7% success rate. Zaslow covers the Consumer Goods sector, focusing on stocks such as Mondelez International, Sanderson Farms, and General Mills.

Currently, the analyst consensus on BellRing Brands is a Strong Buy with an average price target of $31.63, representing a 31.2% upside. In a report issued on January 26, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $33.00 price target.

Optinose (OPTN)

In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Optinose, with a price target of $9.00. The company’s shares closed last Friday at $2.41.

According to TipRanks.com, Nachman has 0 stars on 0-5 stars ranking scale with an average return of -5.7% and a 40.2% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Scholar Rock Holding, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Optinose is a Strong Buy with an average price target of $9.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on REGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed